-
Mashup Score: 4
I’m moderating a small group on Gather-ed, a social learning platform. The curriculum focuses on providing care to patients with advanced and metastatic urothelial carcinoma. Free CME credit is being offered. Please join!
Source: medicallogix.gathered.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms - PubMed - 5 month(s) ago
Immunotherapy has dramatically transformed the cancer treatment landscape largely due to the efficacy of immune checkpoint inhibitors (ICIs). Although ICIs have shown promising results for many patients, the low response rates in many cancers highlight the ongoing challenges in cancer treatment. Cyt …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Excellent work by Shirlyn Wang in print! Exciting team science effort w/ @TrachetteJ @lab_pearson constructing a mathematical model (ODE) to better understand T cell-tumor cell killing dynamics through virtual experiments. https://t.co/NF7Q5LIuxb https://t.co/B5Xlh48y1d
-
-
Mashup Score: 24Sweis Lab | University of Chicago - 5 month(s) ago
Sweis Lab’s mission is to identify and circumvent mechanisms of resistance to cancer immunotherapies and develop the next generation of cancer treatments that benefit every patient.
Source: sweislab.uchicago.eduCategories: General Medicine News, Hem/OncsTweet-
Fully funded postdoctoral scholar positions are now open in our lab in Chicago. We study multiple domains of resistance to cancer immunotherapies with a goal of translating findings to new treatments for patients. https://t.co/NEgtfDKKFf https://t.co/p6YlOqk1kr https://t.co/CysN39fwxQ
-
-
Mashup Score: 7Journal for ImmunoTherapy of Cancer: 10 (Suppl 2) - 2 year(s) ago
November 2022 – Volume 10 – Suppl 2 SITC 37th Annual Meeting (SITC 2022) Abstracts Regular and Young Investigator Award AbstractsBiomarkers, Immune Monitoring and Novel TechnologiesCheckpoint Blockade TherapyClinical Trials CompletedClinical Trials In ProgressCombination ImmunotherapiesData Sharing, Handling and AccessEducation and…
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @jitcancer: The #SITC22 37th Annual Meeting abstract supplement is now live! View the abstracts in #JITC here: https://t.co/vWxpVMFhvL h…
-
-
Mashup Score: 02022 Walk to End Bladder Cancer - Chicago, IL: UChicago Medicine Comprehensive Cancer Center - Bladder Cancer Advocacy Network - 2 year(s) ago
UChicago Medicine Comprehensive Cancer Center We are walking as a team to raise funds for the Bladder Cancer Advocacy Network (BCAN), the only national advocacy organization devoted to advancing bladder cancer research and supporting those impacted by the disease. By making a donation to our team, you will…
Source: secure2.convio.netCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited for the @BladderCancerUS walk on beautiful northerly island in Chicago! Donate to support bladder cancer patients and research: https://t.co/5S26YekWqw @UCCancerCenter https://t.co/WhNKfSKo02 https://t.co/7BUCfTrffw
-
-
Mashup Score: 0
PRINCETON, N.J., March 18, 2022–U.S. FDA Approves First LAG-3-Blocking Antibody Combination, Opdualag as Treatment for Patients with Unresectable or Metastatic Melanoma
Source: finance.yahoo.comCategories: Hem/Oncs, Latest HeadlinesTweet-
No luck this week for for IL-2 cytokine therapy (NKTR-214), but…. Enter Lag-3, the third immune checkpoint with an FDA-approved inhibitor….finally! Welcome relatlimab! https://t.co/rE4NNlhiGo
-
-
Mashup Score: 5FDA approves tebentafusp-tebn for unresectable - 2 year(s) ago
On January 25, 2022, the Food and Drug Administration approved tebentafusp-tebn (Kimmtrak, Immunocore Limited), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Tebentafusp showed OS improvement & is now FDA-approved in uveal melanoma, an immune checkpoint inhibitor-resistant cancer https://t.co/ij6JNUyh6m
-
-
Mashup Score: 0
(Reuters) -Merck & Co said on Friday updated data from its study on its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously reported. The drugmaker said its pill showed a 30% reduction in hospitalizations and deaths, based on data from over 1,400 patients. Merck released the data before the U.S Food and Drug…
Source: news.yahoo.comCategories: Hem/Oncs, Latest HeadlinesTweet-
I’m just gonna leave this here…50% —> 30%. https://t.co/N2D4RhHyTJ
-
-
Mashup Score: 1
Bladder cancer is a common malignancy with over 80,000 estimated new cases and nearly 18,000 deaths per year in the United States alone. Therapeutic options for metastatic bladder cancer had not evol…
Source: Wiley Online LibraryCategories: Hem/Oncs, Latest HeadlinesTweet-
@RenoHemonc @FaltasLab @EricaTrujillo_ @sitcancer Erdafitinib label technically only requires prior platinum, but enfortumab requires prior I/O. That said I actually try I/O before FGFR3 inhibition (due to nuanced clinical reasons). We’ve also published modeling data supporting this approach https://t.co/AODk0fjP8C
-
Join me for this social learning CME online activity. We review the rapidly changing landscape of bladder cancer - it's mostly self-paced and will be fun! New Perspectives in the Front-line Treatment of Metastatic Bladder Cancer https://t.co/fZiFoPW5qA